van der Maaten Joost M A A, de Vries Adrianus J, Rietman Gerrit W, Gallandat Huet Rolf C G, De Hert Stefan G
Department of Anesthesiology, Section of Cardiothoracic Anesthesia, University Medical Center Groningen, Groningen, The Netherlands.
J Cardiothorac Vasc Anesth. 2007 Jun;21(3):357-66. doi: 10.1053/j.jvca.2006.01.006. Epub 2006 May 4.
Left ventricular (LV) hypertrophy is associated with increased diastolic chamber stiffness early after aortic valve replacement for valve stenosis. Enoximone, a phosphodiesterase III inhibitor, has been shown to improve myocardial contractility and relaxation when administered as a single dose after cardiac surgery. The present study investigated, by analysis of transmitral flow velocity patterns and end-diastolic pressure-area relations, whether enoximone administered before aortic valve surgery has an effect on LV diastolic properties.
Prospective, randomized study.
Referral center for cardiothoracic surgery at a university hospital.
Thirty-four patients undergoing aortic valve replacement for aortic stenosis.
Patients in the enoximone group (n = 17) received a bolus dose of 0.35 mg/kg (0.15 mg/kg before aortic cross-clamping and 0.2 mg/kg added to the cardioplegic solution). Individual pressure-area relations (pulmonary capillary wedge pressure v left ventricular end-diastolic area) were obtained by using volume loading by leg elevation before and after surgery with closed chest.
The pressure-area relation on the pressure-area plot was shifted to the left after surgery, indicating decreased LV diastolic distensibility in the enoximone and control groups and providing evidence of decreased LV diastolic function. Indices of LV diastolic chamber stiffness, LV operating stiffness (K(LV)) derived from the deceleration time of early ventricular filling, and the constant of chamber stiffness (beta) derived from pressure-area relations were not different after enoximone treatment. Systolic LV function was unaltered after cardiac surgery in both groups. Analysis of changes in transmitral flow patterns identified an increased atrial filling fraction in enoximone-treated patients, suggesting increased atrial systolic function. The unaltered systolic pulmonary venous flow velocity compared with the decrease in the control group after volume loading further supports preservation of left atrial reservoir function with enoximone in the absence of evidence for decreased LV stiffness.
Preemptive enoximone did not change LV diastolic function based on diastolic filling patterns or LV stiffness indices (K(LV) and beta) derived from Doppler early filling deceleration time and pressure-area relations. Doppler data suggested improvement of left atrial systolic function and preservation of left atrial reservoir function with enoximone.
在因瓣膜狭窄行主动脉瓣置换术后早期,左心室(LV)肥厚与舒张期心室僵硬度增加相关。已证实,依诺昔酮(一种磷酸二酯酶III抑制剂)在心脏手术后单次给药时可改善心肌收缩性和舒张性。本研究通过分析二尖瓣血流速度模式和舒张末期压力-面积关系,探讨在主动脉瓣手术前给予依诺昔酮是否对左心室舒张特性有影响。
前瞻性随机研究。
大学医院心胸外科转诊中心。
34例因主动脉瓣狭窄行主动脉瓣置换术的患者。
依诺昔酮组(n = 17)患者静脉推注剂量为0.35 mg/kg(主动脉阻断前0.15 mg/kg,心脏停搏液中添加0.2 mg/kg)。通过在手术前后闭胸状态下抬高下肢进行容量负荷,获得个体压力-面积关系(肺毛细血管楔压与左心室舒张末期面积)。
术后压力-面积图上的压力-面积关系向左移位,表明依诺昔酮组和对照组左心室舒张期扩张性降低,提示左心室舒张功能降低。依诺昔酮治疗后,左心室舒张期心室僵硬度指标、根据心室早期充盈减速时间得出的左心室工作僵硬度(K(LV))以及根据压力-面积关系得出的心室僵硬度常数(β)并无差异。两组患者心脏手术后左心室收缩功能均未改变。对二尖瓣血流模式变化的分析发现,依诺昔酮治疗患者的心房充盈分数增加,提示心房收缩功能增强。与容量负荷后对照组降低相比,收缩期肺静脉血流速度未改变,这进一步支持了依诺昔酮在无左心室僵硬度降低证据的情况下保留左心房储血功能。
基于舒张期充盈模式或根据多普勒早期充盈减速时间及压力-面积关系得出的左心室僵硬度指标(K(LV)和β),预防性给予依诺昔酮并未改变左心室舒张功能。多普勒数据提示依诺昔酮可改善左心房收缩功能并保留左心房储血功能。